CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 41, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-31
DOI
10.1186/s13046-022-02327-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
- (2021) Ekaterina Zmievskaya et al. Biomedicines
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
- (2021) Xiang-Yuan Luo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Navigating CAR-T cells through the solid-tumour microenvironment
- (2021) Andrew J. Hou et al. NATURE REVIEWS DRUG DISCOVERY
- CAR T cells: Building on the CD19 paradigm
- (2021) Anat Globerson Levin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Novel strategies for immuno-oncology breakthroughs with cell therapy
- (2021) Hongtao Liu et al. Biomarker Research
- Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations
- (2021) Vincent Lemaire et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combination strategies to maximize the benefits of cancer immunotherapy
- (2021) Shaoming Zhu et al. Journal of Hematology & Oncology
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
- (2020) Chongxian Pan et al. Journal of Hematology & Oncology
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
- (2020) Robert David Sandler et al. Frontiers in Immunology
- Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
- (2020) Leila Jafarzadeh et al. Frontiers in Immunology
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
- (2020) Preeti Sharma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
- (2020) Peishan Li et al. NATURE IMMUNOLOGY
- CAR-NK cells: A promising cellular immunotherapy for cancer
- (2020) Guozhu Xie et al. EBioMedicine
- Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity
- (2020) Zhiyuan Niu et al. JOURNAL OF PATHOLOGY
- Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
- (2020) Marsha Pellegrino et al. Cells
- In-Depth Characterization of Monocyte-Derived Macrophages using a Mass Cytometry-Based Phagocytosis Assay
- (2019) Daniel Schulz et al. Scientific Reports
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor T cell persistence and memory cell formation
- (2019) Alexander D McLellan et al. IMMUNOLOGY AND CELL BIOLOGY
- Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
- (2019) Chin-King Looi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
- (2019) Yingxi Xu et al. Journal of Hematology & Oncology
- Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
- (2019) Daniela Pende et al. Frontiers in Immunology
- Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
- (2019) Wenlong Zhang et al. BRITISH JOURNAL OF CANCER
- Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma
- (2019) Zhitao Ying et al. Molecular Therapy-Oncolytics
- Developing neoantigen-targeted T cell–based treatments for solid tumors
- (2019) Tori N. Yamamoto et al. NATURE MEDICINE
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production
- (2018) Xuhua Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
- (2018) May Daher et al. CURRENT OPINION IN IMMUNOLOGY
- The expansion of targetable biomarkers for CAR T cell therapy
- (2018) Michelle H. Townsend et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptors that trigger phagocytosis
- (2018) Meghan A Morrissey et al. eLife
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium
- (2018) Andrew R. Medvec et al. Molecular Therapy-Methods & Clinical Development
- ASBMT Pharmacy Special Interest Group Survey on CAR T Cell Therapy Administrative, Logistical and Toxicity Management Practices in the United States
- (2018) Zahra Mahmoudjafari et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
- (2018) Haiying Qin et al. Molecular Therapy-Oncolytics
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
- (2017) James N. Kochenderfer et al. MOLECULAR THERAPY
- Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
- (2017) Kevin Bielamowicz et al. NEURO-ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous lymphapheresis for the production of chimeric antigen receptor T cells
- (2017) Elizabeth S. Allen et al. TRANSFUSION
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
- (2016) Kole T. Roybal et al. CELL
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- The impact of hypoxia on tumor-associated macrophages
- (2016) Anne-Theres Henze et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Macrophages and Therapeutic Resistance in Cancer
- (2015) Brian Ruffell et al. CANCER CELL
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
- (2015) H. G. Caruso et al. CANCER RESEARCH
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphoinositide 3-kinase enables phagocytosis of large particles by terminating actin assembly through Rac/Cdc42 GTPase-activating proteins
- (2015) Daniel Schlam et al. Nature Communications
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
- (2015) A. Kunkele et al. Cancer Immunology Research
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Are natural killer cells superior CAR drivers?
- (2014) Hans Klingemann OncoImmunology
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
- (2013) Eric Tran et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach
- (2013) Connie P. M. Duong et al. PLoS One
- Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
- (2013) L.-C. S. Wang et al. Cancer Immunology Research
- An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo
- (2012) T. Zhang et al. JOURNAL OF IMMUNOLOGY
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
- (2012) De-Gang Song et al. OncoImmunology
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Terminating the immune response
- (2010) Philippa Marrack et al. IMMUNOLOGICAL REVIEWS
- The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3 Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
- (2010) J. S. Bridgeman et al. JOURNAL OF IMMUNOLOGY
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now